Comprehensive analysis of transcriptomic biomarkers for predicting response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma

Saved in:
Bibliographic Details
Main Authors: Binghua Li, Jingyuan Wen, Zhu Xu, Peng Yan, Bing Han, Decai Yu
Format: Article
Language:English
Published: Korean Association for the Study of the Liver 2025-01-01
Series:Clinical and Molecular Hepatology
Subjects:
Online Access:http://e-cmh.org/upload/pdf/cmh-2024-0628.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850045429194948608
author Binghua Li
Jingyuan Wen
Zhu Xu
Peng Yan
Bing Han
Decai Yu
author_facet Binghua Li
Jingyuan Wen
Zhu Xu
Peng Yan
Bing Han
Decai Yu
author_sort Binghua Li
collection DOAJ
format Article
id doaj-art-5cedd165e5e2462b8f83eef50dc1f1f3
institution DOAJ
issn 2287-2728
2287-285X
language English
publishDate 2025-01-01
publisher Korean Association for the Study of the Liver
record_format Article
series Clinical and Molecular Hepatology
spelling doaj-art-5cedd165e5e2462b8f83eef50dc1f1f32025-08-20T02:54:42ZengKorean Association for the Study of the LiverClinical and Molecular Hepatology2287-27282287-285X2025-01-01311e31e3410.3350/cmh.2024.06282040Comprehensive analysis of transcriptomic biomarkers for predicting response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinomaBinghua Li0Jingyuan Wen1Zhu Xu2Peng Yan3Bing Han4Decai Yu5 Division of Hepatobiliary and Transplantation Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China Division of Hepatobiliary and Transplantation Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China Department of Hepatobiliary Surgery, Innovative Institute of Tumor Immunity and Medicine (ITIM), Anhui Province Key Laboratory of Tumor Immune Microenvironment and Immunotherapy, The First Affiliated Hospital of Anhui Medical University, Hefei, China Division of Hepatobiliary and Transplantation Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China Division of Hepatobiliary and Transplantation Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China Division of Hepatobiliary and Transplantation Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Chinahttp://e-cmh.org/upload/pdf/cmh-2024-0628.pdfhepatocellular carcinomaimmunotherapyatezolizumab plus bevacizumabbiomarkerimmune checkpoint inhibitors
spellingShingle Binghua Li
Jingyuan Wen
Zhu Xu
Peng Yan
Bing Han
Decai Yu
Comprehensive analysis of transcriptomic biomarkers for predicting response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma
Clinical and Molecular Hepatology
hepatocellular carcinoma
immunotherapy
atezolizumab plus bevacizumab
biomarker
immune checkpoint inhibitors
title Comprehensive analysis of transcriptomic biomarkers for predicting response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma
title_full Comprehensive analysis of transcriptomic biomarkers for predicting response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma
title_fullStr Comprehensive analysis of transcriptomic biomarkers for predicting response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma
title_full_unstemmed Comprehensive analysis of transcriptomic biomarkers for predicting response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma
title_short Comprehensive analysis of transcriptomic biomarkers for predicting response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma
title_sort comprehensive analysis of transcriptomic biomarkers for predicting response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma
topic hepatocellular carcinoma
immunotherapy
atezolizumab plus bevacizumab
biomarker
immune checkpoint inhibitors
url http://e-cmh.org/upload/pdf/cmh-2024-0628.pdf
work_keys_str_mv AT binghuali comprehensiveanalysisoftranscriptomicbiomarkersforpredictingresponsetoatezolizumabplusbevacizumabimmunotherapyinhepatocellularcarcinoma
AT jingyuanwen comprehensiveanalysisoftranscriptomicbiomarkersforpredictingresponsetoatezolizumabplusbevacizumabimmunotherapyinhepatocellularcarcinoma
AT zhuxu comprehensiveanalysisoftranscriptomicbiomarkersforpredictingresponsetoatezolizumabplusbevacizumabimmunotherapyinhepatocellularcarcinoma
AT pengyan comprehensiveanalysisoftranscriptomicbiomarkersforpredictingresponsetoatezolizumabplusbevacizumabimmunotherapyinhepatocellularcarcinoma
AT binghan comprehensiveanalysisoftranscriptomicbiomarkersforpredictingresponsetoatezolizumabplusbevacizumabimmunotherapyinhepatocellularcarcinoma
AT decaiyu comprehensiveanalysisoftranscriptomicbiomarkersforpredictingresponsetoatezolizumabplusbevacizumabimmunotherapyinhepatocellularcarcinoma